^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TargomiR (EGFREDVmiR-16)

    i
    Other names: EGFREDVmiR-16, microRNA encapsulated nanocells, microRNA packaged EDV nanocells
    Associations

    News

    Trials
    Company:
    Asbestos Diseases Research Institute, EnGeneIC
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    5ms
    MicroRNAs: Novel clinical biomarkers for cancer radiotherapy (Review). (PubMed, Mol Med Rep)
    Despite the early challenges of miRNA‑based therapies, advancements in miRNA delivery systems, including TargomiR‑ and liposome‑based approaches, offer promising avenues for clinical applications. The present review highlights the role of miRNAs as biomarkers and modulators in cancer radiotherapy and discusses ongoing research on miRNA delivery mechanisms to improve therapeutic outcomes. Future studies are needed to address the challenges of miRNA pleiotropy and safety in clinical applications, to advance miRNA‑based interventions in precision oncology, and to enhance the efficacy of radiotherapy across various cancer types.
    Review • Journal
    |
    MIR200C (MicroRNA 200c)
    |
    TargomiR (EGFREDVmiR-16)